Arteris raises FY 2026 revenue outlook to $95M-$98M as ACV plus royalties targets $102M-$106M

Neurocrine expects double-digit 2027 INGREZZA volume growth despite mid- to high single-digit net pricing headwinds

Ichor signals full year 2026 revenue growth of roughly 30% while targeting 16.5% Q4 gross margin

Fabrinet anticipates Q2 revenue of $1.6B-$1.65B while starting Building 11 with ~$3B capacity

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M